| Michelle Brown, | |
|
16359 Sussex Hwy, Bridgeville, DE 19933-2966 | |
| (302) 337-3469 | |
| Not Available |
| Full Name | Michelle Brown |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 16359 Sussex Hwy, Bridgeville, Delaware |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144364951 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 010000439 (Delaware) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michelle Brown, 16359 Sussex Hwy, Bridgeville, DE 19933-2966 Ph: (302) 337-7990 | Michelle Brown, 16359 Sussex Hwy, Bridgeville, DE 19933-2966 Ph: (302) 337-3469 |
News Archive
Patients with septic shock who were treated with norepinephrine earlier than patients receiving standard care were more likely to have their blood pressure and shock stabilized within six hours of diagnosis, according to a randomized, double-blind, controlled trial published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
For years, the advice to the overweight and obese has been that we simply need to eat less and exercise more. While there is truth to this guidance, it fails to take into account that the human body continues to fight against weight loss long after dieting has stopped. ... it's clear, from a public-health standpoint, that resources would best be focused on preventing weight gain. The research underscores the urgency of national efforts to get children to exercise and eat healthful foods.
A survey finds that hospital-based general practitioners feel overburdened by patient loads to the point where it has a negative impact on patient assessments, satisfaction and possibly safety outcomes.
Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.
Bioheart has announced that the U.S. Patent and Trademark Office issued the company a notice of allowance regarding its patent application 09/858,046, entitled Method For Inducing Angiogenesis By Electrical Stimulation of Muscles.
› Verified 3 days ago
Susan J. Howlett, M.A. CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 32 Canvasback Cir, Bridgeville, DE 19933 Phone: 302-670-1055 |